Infectious Disease AdvisorReal-World Data Highlight Effectiveness of XBB.1.5-Adapted COVID-19 Vaccines

This systematic review and network meta-analysis of 28 publications evaluated real-world vaccine effectiveness of XBB.1.5-adapted mRNA vaccines against Omicron variants. The study methodology included comparative analysis of bivalent BA.4/5, monovalent XBB.1.5, JN.1, and KP.2 formulations with follow-up data extending to 56 days post-vaccination.

⚕️ Key Clinical Considerations ⚕️

• Modest infection prevention: XBB.1.5-adapted vaccines showed 36% effectiveness against XBB-related infection (95% CI, -43 to 72) at 56 days post-vaccination.
• Limited hospitalization protection: Overall vaccine effectiveness against COVID-19-related hospitalization was 16% (95% CI, -26 to 43) across age groups.
• Age-stratified benefits: Older populations demonstrated improved hospitalization protection with BNT162b2 XBB.1.5 vaccines (VE 26%, 95% CI 5-40%).
• Platform differences: Single-study data suggested BNT162b2 outperformed mRNA-1273 by 86.1% for infection prevention and 82.2% for hospitalization prevention.
• Evidence limitations: Analysis relied on observational studies with varying follow-up periods and insufficient population characteristic data.

🎯 Clinical Practice Impact 🎯

• Patient Communication: Counsel patients that XBB.1.5-adapted vaccines provide modest protection against infection and hospitalization, with effectiveness varying by age and vaccine manufacturer.
• Practice Integration: Prioritize XBB.1.5-adapted vaccination in older adults where hospitalization benefits are more pronounced.
• Risk Management: Consider individual patient risk factors when discussing vaccine expectations, acknowledging wide confidence intervals in effectiveness data.
• Action Items: Monitor emerging data on newer variant-adapted formulations and adjust recommendations based on local variant predominance patterns.

More in Infectious Diseases